ACT News Alert Actavis Inc (ACT) 245.32 11/05/2014 04:53:59

New Post Public Reply Private Reply Replies (0) Message Board

Nov 5, 2014 at 5:53 AM

Actavis Inc (ACT) 245.32 $ACT

These 5 Drugmakers' Earnings Excelled This Quarter
at Investor's Business Daily - Tue Nov 04, 7:14PM CST
Big pharma firms such as Alexion Pharmaceuticals and Biogen Idec continue to outperform the market as they develop and market new treatments to treat long-time targets such as Alzheimer's as well as rare illnesses. Today's Screen Of The Day is Big...
AGN: 195.12 (+1.98), BIIB: 322.06 (+0.81), VRX: 133.61 (+0.76), ACT: 245.32 (-2.18), JAZZ: 168.48 (-1.85), ALXN: 191.30 (+0.26), CELG: 105.75 (-1.66)

Stocks End Mixed; Jazz Pharma Rises After Hours
at Investor's Business Daily - Tue Nov 04, 4:11PM CST
Stocks closed mixed, as earnings reports shook some stocks after the bell. The Nasdaq and S&P 500 dropped 0.3%, and the Dow Jones industrial average gained 0.1%. Volume was higher on the NYSE and lower on the Nasdaq, according to preliminary figures....
TSLA: 238.93 (-3.66), ACT: 245.32 (-2.18), FEYE: 34.25 (+0.56), AWAY: 33.75 (-1.11), CYBR: 36.53 (-0.05), JAZZ: 168.48 (-1.85), TRIP: 83.79 (-1.42), PANW: 106.71 (+0.75), ATHM: 50.19 (-0.40)

Will ARIAD (ARIA) Miss This Earnings Season? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Nov 04, 4:00PM CST
ARIAD Pharmaceuticals, Inc. (ARIA) has Earnings ESP of 0.00% and a Zacks Rank #4 (Sell).
MNK: 94.09 (+0.66), ACT: 245.32 (-2.18), ARIA: 5.88 (-0.05), HSP: 53.28 (+0.26)

Will Endocyte (ECYT) Miss This Earnings Season? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Nov 04, 3:50PM CST
Endocyte, Inc. (ECYT) has Earnings ESP of 0.00% and a Zacks Rank #2 (Buy).
ACT: 245.32 (-2.18), ECYT: 5.70 (-0.10), MRK: 59.37 (+0.45), HSP: 53.28 (+0.26)

Will Perrigo (PRGO) Disappoint This Earnings Season? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Nov 04, 3:45PM CST
Perrigo (PRGO), which is scheduled to report first-quarter fiscal 2015 results on Nov 6, had delivered a positive earnings surprise of 12.26%.
MDVN: 103.83 (-1.57), ACT: 245.32 (-2.18), PRGO: 159.85 (-0.10), ALNY: 89.99 (-2.57)

Will Keryx Biopharmaceuticals (KERX) Post Wider Q3 Loss? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Nov 04, 3:35PM CST
Keryx Biopharmaceuticals, Inc.'s (KERX) is scheduled to report its third-quarter 2014 results on Nov 6.
MNK: 94.09 (+0.66), ACT: 245.32 (-2.18), HSP: 53.28 (+0.26), KERX: 16.30 (-0.15)

Video: Top 3 Earnings Reports To Watch Wednesday
at Investor's Business Daily - Tue Nov 04, 12:45PM CST
Several highly rated tech companies and drugmakers are set to report earnings on Wednesday. Here's a look at what analysts expect. Actavis (ACT) reports its results before the open. The specialty-drug giant is projected to earn $3.10 a share, a 48%...
AGN: 195.12 (+1.98), TSLA: 238.93 (-3.66), VRX: 133.61 (+0.76), ACT: 245.32 (-2.18), ATHM: 50.19 (-0.40)

Should You Buy Actavis (ACT) Ahead of Earnings? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Nov 04, 7:54AM CST
Actavis is seeing favorable earnings estimate revision activity and an earnings beat might be in the cards for the upcoming report.
ACT: 245.32 (-2.18)

Salix, Skyworks Lead 6 IBD50 EarningsReports On Tap
at Investor's Business Daily - Tue Nov 04, 7:02AM CST
Earnings season continues to barrel forward, and investors are anticipating results from several top drugmakers this upcoming week. This week's IBD 50, a roundup of top-rated growth stocks with solid fundamentals, boasts six companies reporting...
DRTX: 23.98 (-0.05), AGN: 195.12 (+1.98), ACT: 245.32 (-2.18), SWKS: 60.42 (+0.19), AKRX: 42.64 (-1.18), JAZZ: 168.48 (-1.85), SLXP: 140.45 (-2.74), AAPL: 108.60 (-0.80), ATHM: 50.19 (-0.40)

Can Cognizant (CTSH) Keep the Earnings Streak Alive? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Nov 03, 5:12PM CST
Cognizant Technology Solutions Corp (CTSH) is set to report third quarter 2014 results on Nov 5.
ACT: 245.32 (-2.18), DIS: 90.35 (-1.36), ACN: 81.15 (+0.18), CTSH: 48.49 (-0.40)

Will Actavis (ACT) Beat Earnings Estimates on Forest Deal? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Nov 03, 4:20PM CST
Actavis (ACT) is scheduled to report third-quarter 2014 results before the opening bell on Nov 5.
MNK: 94.09 (+0.66), ACT: 245.32 (-2.18), ALNY: 89.99 (-2.57), HSP: 53.28 (+0.26)

Is Hospira (HSP) Poised to Beat Q3 Earnings Estimates? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Nov 03, 4:00PM CST
Hospira (HSP), which is scheduled to report third-quarter 2014 results on Nov 6, had posted a positive earnings surprise of 28.57%.
MDVN: 103.83 (-1.57), ACT: 245.32 (-2.18), ALNY: 89.99 (-2.57), HSP: 53.28 (+0.26)

Will Covidien (COV) Disappoint Earnings Estimates in Q4? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Nov 03, 2:00PM CST
Covidien plc (COV) is set to report fourth-quarter fiscal 2014 results on Nov 5.
ACT: 245.32 (-2.18), MDT: 67.93 (-0.22), COV: 92.03 (-0.39), HSIC: 120.84 (+1.13)

Will Exelixis (EXEL) Disappoint This Earnings Season? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Nov 03, 1:35PM CST
Exelixis, Inc. (EXEL) is slated to report its third-quarter 2014 results on Nov 4.
ACT: 245.32 (-2.18), HSP: 53.28 (+0.26), EXEL: 1.65 (-0.05)

Will Zoetis (ZTS) Pull a Surprise this Earnings Season? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Oct 31, 4:10PM CDT
Zoetis Inc. (ZTS) is scheduled to report third-quarter 2014 results before the opening bell on Nov 4.
ZTS: 39.12 (+1.40), ACT: 245.32 (-2.18), PFE: 30.28 (+0.09), HSP: 53.28 (+0.26)

Bristol-Myers Squibb Up on Positive Opdivo Phase II Study - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Oct 31, 3:46PM CDT
Bristol-Myers Squibb Company announced encouraging data from the phase II CheckMate - 063 study on immuno-oncology drug Opdivo.
MNK: 94.09 (+0.66), AGN: 195.12 (+1.98), ACT: 245.32 (-2.18), BMY: 57.84 (+0.04)

Stocks End Week On Fine Note; LinkedIn Surges On Earnings
at Investor's Business Daily - Fri Oct 31, 3:29PM CDT
The market enjoyed another shot of institutional buying Friday, cheered by additional -- and unexpected -- stimulus measures by the Bank of Japan. Another round of healthy earnings reports and a rise in U.S. consumer confidence also fueled positive...
AMBA: 45.48 (-2.08), TSLA: 238.93 (-3.66), GPRO: 82.27 (-2.05), ACT: 245.32 (-2.18), FRGI: 55.42 (+0.20), LNKD: 238.43 (+5.35), JAZZ: 168.48 (-1.85), FLT: 148.53 (-1.70), EPAM: 46.61 (-1.10), REGN: 372.39 (-22.87), BABA: 106.07 (+4.27)

Actavis and Durata Therapeutics Receive U.S. FTC Clearance for Actavis' Proposed Acquisition of Durata
PR Newswire - Fri Oct 31, 3:15PM CDT
Actavis plc (NYSE: ACT) and Durata Therapeutics, Inc. (NASDAQ: DRTX) today announced that the U.S. Federal Trade Commission (FTC) has granted early termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 ("HSR"

with respect to Actavis' pending acquisition of Durata.
DRTX: 23.98 (-0.05), ACT: 245.32 (-2.18)

Will Arena Pharma (ARNA) Q3 Loss Be Wider than Expected? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Oct 31, 2:34PM CDT
Arena Pharmaceuticals (ARNA) is scheduled to report its third-quarter 2014 results before the opening bell on Nov 3.
ACT: 245.32 (-2.18), ARNA: 4.31 (+0.09), HSP: 53.28 (+0.26)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

MRI Surveillance Gains Ground in Lung Cancer Care

Shifting the Standard: MRI's Rise in SCLC Treatment Here's a twist that baffles the traditionalists—ditch the prophylactic cranial irradiation (PCI) and catch clearer days with MRI surveillance for small-cell lung cancer (SCLC). The latest international phase III MAVERICK trial might just redraw the lines on what's considered standard care in this relentless disease....

PwC US and India Unite for Global Consultancy Powerhouse

Rearranging the Consultancy Chessboard Piling onto the game of consultancy realignments, PwC just made a move reminiscent of playing strategy poker. They're tossing together PwC US and PwC India's advisory capabilities for a new joint venture. It’s like pushing two puzzle pieces to make a single colorful picture that stretches from the U.S. all the way to the...

GORGIE Unleashes Berry Burst: Target's New Drink Star

GORGIE Targets Taste Buds with Berry Burst Ever feel like you're missing out on that energy drink everyone seems to be raving about? Well, GORGIE's out there making some noise again, and this time it's got a new punchy player in the game: Berry Burst. It's not just another drink; it's shaking things up in the energy aisle with its exclusive launch at Target. Modern style...

Regeneron Faces Legal Heat: Lead Plaintiff Deadline Looms

Regeneron’s Tight Spot: Legal Showdown Well, here we go again—Regeneron Pharmaceuticals (NASDAQ:REGN) is under some serious heat. If you're an investor who faced significant losses with this biotech juggernaut, remember that the clock’s ticking down to the wire. By tomorrow, September 14, 2026, you need to decide if you're going to throw your hat in the ring for...

PANDAG G1 Debuts: Revolutionizing Lawn Care Efficiency

The Future of Landscaping Unveiled Get this—PANDAG is set to shake things up at GaLaBau 2026 with their futuristic G1 autonomous mower. This isn't just another piece of lawn equipment; it's practically a tech marvel on wheels, weaving together LiDAR, AI Vision, RTK, and 4G tech to make it the ultimate multitasker for the landscaping industry. We're talking obstacle...

First-Time Homeowners: Unseen Pitfalls of Insurance

Understanding Homeowners Insurance: Beyond the Basics Most folks diving into homeownership for the first time get caught up in the whirlwind of price tags, loans, and knick-knacks for their new place. Meanwhile, the nitty-gritty of homeowners insurance often gets tossed to the side. But take it from a weary watchdog of financial storms—it’s those details in the policy...

Ris-Rez May Set New Standard in Relapsed SCLC

The Game-Changing Results Innovation in pharmaceuticals sometimes feels like a waiting game, but when a fresh breakthrough like this rolls in, it lights up the whole landscape. Risvutatug rezetecan, or Ris-Rez for short, has shown promising potential in the fight against relapsed small-cell lung cancer (SCLC) that has progressed after platinum-based therapy. Survival...

Surfing Dogs Ride Waves, Support Orphan Pets

Waves, Paws, and Passion Who would've thought that dogs catching waves could also catch hearts and wallets? Well, that's exactly what's happening today at Del Mar Dog Beach with the 21st Annual Surf Dog Surf-A-Thon revving up the excitement. It's a sun-soaked day in Rancho Santa Fe, California, right in the thick of things at the longest-running dog surf competition. For...

Tam-Peli Steps Up in SCLC Battle: Trial Insights

Noteworthy Developments in Small-Cell Lung Cancer Treatment Let's dive into a story straight from the world of small-cell lung cancer (SCLC) that doesn't take any prisoners. The antidote making waves is tambotatug pelitecan, or Tam-Peli for short, showcasing its might in the unrelenting fight against relapsed SCLC. The phase III TAISHAN-302 trial puts Tam-Peli...

UWM Faces Class Action Deadline: Key Insights for Investors

The High Stakes Reality for UWM Investors If there's one thing that's certain in this jittery world of investing, it's that losses have a way of waking you up. Right now, anyone tied up with UWM Holdings Corporation (NYSE: UWMC) shares needs to keep their wits about them; we're barreling toward an October 13, 2026 deadline for a class action lawsuit. The clock's ticking...